Tamara Wyse, MD
Ophthalmology · Northbrook, ILNPI 1881609642
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Alcon at 39.6% of the total. Reporting peaked in 2024 at $2,383 and has fallen 80.5% since, to $465 in 2025.
Across 110 payments — averaging $58.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Novartis$480
- NEW World Medical,inc.$480
- AbbVie$315
- Lumenis BE Inc$145
- plus $655 from 8 others
Across 13 payments — averaging $19,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$128K
- Ocular Therapeutix, Inc.$90K
- Oyster Point Pharma, Inc.$32K
- Tarsus Pharmaceuticals, Inc.$800
What the payments were for
- Consulting fees$2,03232%
- Speaking & faculty fees$391%
- Travel & lodging$1,81428%
- Food & beverage$2,54940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 26 | $2,550 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,809 |
| Novartis | 28 | $480 |
| NEW World Medical,inc. | 4 | $480 |
| AbbVie(2 entities) | 21 | $315 |
| Lumenis BE Inc | 1 | $145 |
| Rayner Intraocular Lenses Limited | 1 | $143 |
| Ocular Therapeutix, Inc. | 8 | $140 |
| Harrow Eye, LLC | 4 | $98 |
| Rxsight Inc | 2 | $74 |
| Aerie Pharmaceuticals, Inc. | 4 | $69 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $65 |
| Shire North American Group Inc | 2 | $45 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$1,801
- Tecnis Symfony IOL$1,732
- Ahmed Glaucoma Valve$471
- Kahook Dual Blade$471
- Clearpath$171
- Streamline$171
- Via360$171
- M22$145
- RAYNER CATARACT SET 1$143
- RayOne EMV$143
- RayOne Spheric$143
- RayOne Aspheric$143
How this compares
$6,434 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 218 | $288,593 |
| XdemvyLotilaner | 84 | $155,463 |
| ProlensaBromfenac Sodium | 303 | $132,912 |
| XiidraLifitegrast | 73 | $110,525 |
| Cyclosporine | 83 | $43,687 |
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $35,172 |
| RhopressaNetarsudil Mesylate | 69 | $33,810 |
| Prednisolone Acetate | 758 | $25,005 |
| LumiganBimatoprost | 30 | $20,247 |
| VevyeCyclosporine | 23 | $17,208 |
| MoxifloxacinMoxifloxacin Hcl | 688 | $16,663 |
| Travoprost | 82 | $16,026 |
| Alphagan PBrimonidine Tartrate | 24 | $15,840 |
| TyrvayaVarenicline Tartrate | 24 | $15,631 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $15,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $315 | $336,857296 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $65 | $134,836316 claims |
| Bausch & Lomb Americas Inc.Xiidra | $21 | $110,52573 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $69 | $68,981120 claims |
| Harrow Eye, LLCVevye | $98 | $17,20823 claims |
| AlconSimbrinza | $2,550 | $15,30464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Northbrook
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.